RiteMED Febuxostat Dosage/Direction for Use

Adults: The recommended oral dose of FEBUXOSTAT is 40 mg once daily with or without food, depending on the baseline serum uric acid (sUA) levels (20 mg if sUA <7.5 mg/dL; 40 mg if sUA >8.0 mg/dL). If serum uric acid is >6 mg/dL (357 μmol/l) after 2-4 weeks, the dosage may be increased to 120 mg once daily. FEBUXOSTAT works sufficiently quickly to allow retesting of the serum uric acid after 2 weeks. The therapeutic target is to decrease and maintain serum uric acid below 6 mg/dL (357 μmol/l). Gout flare prophylaxis of at least 6 months is recommended. Or, as prescribed by the physician.
Elderly: No dose adjustment is required in the elderly.
Children (<18 years): As there has been no experience in children and adolescents, the use of FEBUXOSTAT in such patients is not recommended.
Renal Impairment: No dose adjustment is necessary in patients with mild to moderate renal impairment. The efficacy and safety have not been fully evaluated in patients with severe renal impairment (creatinine clearance <30 mL/min).
Hepatic Impairment: The recommended dosage in patients with mild hepatic impairment is 80 mg. Limited information is available in patients with moderate hepatic impairment.
The efficacy and safety of FEBUXOSTAT has not been studied in patients with severe hepatic impairment (Child Pugh Class C).